HGS1029-C1080

• Research type

  Research Study

• Full title

  A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory B-Cell Neoplasms: Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma or Non-Hodgkin’s Lymphoma

• IRAS ID

  27207

• Contact name

  Anna Schuh

• Sponsor organisation

  Human Genome Sciences Inc.

• Eudract number

  2009-009234-32

• ISRCTN Number

  n/a

• Research summary

  HGS1029 is part of a new class of compounds that blocks the actions of certain proteins (Inhibitor of Apoptosis Proteins) thereby stimulating the death of cancer cells.

  The purpose of the study is to test this experimental drug on patients with either Chronic Lymphocytic Leukemia (CLL), Small Cell Lymphocytic Lymphoma (SLL), or Non-Hodgkin’s Lymphoma (NHL) who have not responded to previous treatments or where there are no further curative treatments available.

  The primary purpose of this study is to find out how much of the study drug (HGS1029) can be given safely to patients with Chronic Lymphocytic Leukemia, Small Cell Lymphoma or Non-Hodgkin’s Lymphoma.

  A secondary purpose of this study is to examine proteins in the blood that may provide an early indication that the treatment is working or failing. Another secondary purpose of this study is to measure the amount of HGS1029 in the patients blood during study treatment.

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  09/H1306/92

• Date of REC Opinion

  18 Dec 2009

• REC opinion

  Further Information Favourable Opinion